ARROWHEAD PHARMACEUTICALS, INC. (ARWR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US04280A1007
ARROWHEAD PHARMACEUTICALS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 829.45 m USD |
| Operating income | 98.35 m USD |
| EBIT | 103.61 m USD |
| Net income | -1.63 m USD |
| Diluted EPS – continuing operations | -0.01 USD |
Full history since 1997, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ARROWHEAD PHARMACEUTICALS, INC.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
More stocks
- Vibra Energia S.A. (VBBR3.SA)
- OSHKOSH CORP (OSK)
- Railway Signal Communication Ltd (688009.SS)
- APTARGROUP, INC. (ATR)
- Metlen Energy & Metals PLC (MTLN.L)
- Hyundai Rotem Co (064350.KS)
- TIMKEN CO (TKR)
- CapitaLand Ascendas REIT (A17U.SI)
- Guangzhou Tinci Materials Technology Co Ltd (002709.SZ)
- Wynn Resorts (WYNN)
- Metallurgical Corporation of China Ltd (601618.SS)
- Molson Coors Beverage Company (TAP)
Not investment advice. All data without warranty, price as of 16.10.2026. Details in the risk notice.